Sodium Fluorescein Staining of the Cornea for the Diagnosis of Dry Eye: A Comparison of Three Eye Solutions by CHEN, Ming et al.
 
 
Med Hypothesis Discov Innov Ophthalmol. 2017; 6(4)  
 
 
Original Article 
              Medical Hypothesis, Discovery & Innovation 
Ophthalmology Journal 
 
 
 
Sodium Fluorescein Staining of the Cornea for the Diagnosis of 
Dry Eye: A Comparison of Three Eye Solutions 
 
Ming CHEN 1; Maile MIKI 1; Szuyuan LIN 2; So YUNG CHOI 1 
 
1. John A. Burns School of Medicine, University of Hawaii, USA 
2. Cathay General Hospital, Taipei, Taiwan 
 
ABSTRACT 
The purpose of this study was to identify which of the eye solutions is best for sodium fluorescein staining 
of the cornea to diagnose dry eye disease. The study included 173 eyes with suspected or known dry eye 
disease. The eyes were stained sequentially with sodium fluorescein and each of the following four 
conditions: balanced salt solution (BSS); BSS and cyclosporine 0.05% emulsion; BSS and lipids containing 
omega-3; and BSS, cyclosporine 0.05% emulsion, and lipids containing omega-3. Our results showed that 
compared to BSS alone, artificial tears with cyclosporine 0.05% emulsion and lipids containing omega-3 
remain in the cornea for longer periods, thus allowing the clinician to evaluate tear break-up time and 
visualize corneal punctate erosions. 
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INTRODUCTION
According to the National Eye Institute, it is estimated 
that 5 million Americans over the age of 50 have dry eye 
disease (DED) [1]. Many cases remain undiagnosed until 
they progress to a severe stage that is very difficult to 
treat. The International Dry Eye Workshop
 
II (DEWS II) 
stated, “dry eye disease is a multifactorial disease of the 
ocular surface characterized by a loss of homeostasis of 
the tear film, and accompanied by ocular symptoms, in 
which tear film instability and hyperosmolarity, ocular 
surface inflammation and damage, and neurosensory 
abnormalities play etiological roles” [2]. There are two 
types of dry eye, aqueous-deficient and evaporative dry 
eye, with the evaporative type being the most common 
[3]. In some cases, both types occur simultaneously, 
which is referred to as mixed DED [2]. Tears comprise 
three layers: the outer lipid layer, the middle aqueous 
layer, and the inner mucin layer [4]. Aqueous-deficient 
DED is caused by the lack of lacrimal gland production of 
the aqueous layer. Evaporative DED is a result of the lack 
of quality of the lipid layer from the Meibomian glands 
[5]. Dry eye can be caused by a variety of factors, 
including medications, age, autoimmune disorders, 
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allergies, corneal surgeries, and the environment [6]. 
Unfortunately, DED is under-diagnosed and under-
treated. DED goes unnoticed because patients may not 
realize their symptoms are treatable, and thus do not 
discuss them with their doctors. Moreover, many 
physicians are not proactive in investigating DED 
symptoms and signs [7]. Beyond eye symptoms, DED can 
affect an individual’s overall health, impacting one’s 
quality of life. This includes aspects of “physical, social, 
psychological functioning daily activities and workplace 
productivity” [8]. There is even a significant correlation 
between DED and sleep and mood disorders [9]. Because 
DED is a chronic condition that can be debilitating, it is 
imperative to find ways to improve diagnosis of DED, so 
patients can seek appropriate management and care as 
soon as possible [10]. We conducted a prospective study 
to identify which of the eye solutions is best for sodium 
fluorescein staining of the cornea to evaluate tear break-
up time (TBUT) and visualize punctate erosions in 
patients with suspicious or known DED. To our 
knowledge, this is the first study of its type with this 
methodology. 
 
 
Figure 1. Flow Chart of Eyes Stained with Different Solutions. 
BSS: Balanced Salt Solution 
 
 
Figure 2. Sodium Fluorescein in Balanced Salt Solution (BSS) 
revealed no Discernible Punctate Staining on the Cornea (top); 
the Same Eye was Subsequently Stained with Sodium 
Fluorescein in BSS + Cyclosporine 0.05% Emulsion, and Obvious 
Punctate Staining was Observed (Bottom). 
 
MATERIALS AND METHODS 
All patients signed a consent form in order to be included 
in this study, and the study received ethical approval at 
the department level. This prospective controlled study 
compared the efficacy of sodium fluorescein in balanced 
salt solution (BSS) solution, lipid-based artificial tears 
containing omega-3, and/or cyclosporine 0.05% emulsion 
in evaluating TBUT, visualizing corneal punctate staining, 
and diagnosing DED. The ingredients of each solution are 
listed in Table 1. The inclusion criterion was eyes with 
suspected or known DED.  
Differential diagnosis of aqueous-deficient or evaporative 
DED was not performed due to higher costs and longer 
 
 
Med Hypothesis Discov Innov Ophthalmol. 2017; 6(4)  
 
107 COMPARISON OF THREE EYE SOLUTIONS IN DRY EYE 
times to testing. Therefore, the study population 
probably included both types. The exclusion criteria were 
eyes with severe eye disease, such as corneal ulcers, 
endophthalmitis, phthisis bulbi, acute conjunctivitis, and 
dacryocystitis. The solutions were tested sequentially for 
comparison. There were three solutions but four 
conditions: 1) BSS; 2) BSS and cyclosporine 0.05% 
emulsion; 3) BSS and lipids containing omega-3; and 4) 
BSS, cyclosporine 0.05% emulsion, and lipids containing 
omega-3. All eyes were stained with sodium fluorescein 
strips in BSS first. The eyes that showed no or faint 
sodium fluorescein strip staining were re-stained 
immediately with sodium fluorescein strips in either BSS 
+ cyclosporine 0.05% emulsion or BSS + lipids containing 
omega-3. If the eyes stained with BSS + lipids containing 
omega-3 failed to show any corneal punctate staining, 
BSS + cyclosporine 0.05% emulsion was tested (Fig 1). All 
eyes were examined with a slit lamp under cobalt blue 
light by one of the authors (M.C.). Descriptive statistics 
were calculated to summarize patient demographics and 
medical information. The staining rate for each condition 
was calculated, together with its 95% confidence interval 
(Fig 2). The rate of either observing staining on the 
cornea with fluorescein or no staining observed. 
RESULTS 
In this study, 173 right eyes from 173 patients met the 
inclusion criterion. The average age of the 173 patients 
was 68 years old, and 73% of them were women.  
The difference between the BSS and the cyclosporine 
0.05% emulsion is the main active ingredient, 
cyclosporine 0.05%, in a glycerin-in-castor oil emulsion 
(Table 1). 
The difference between the cyclosporine 0.05% emulsion 
and the lipid-based artificial tears containing omega-3 is 
also cyclosporine 0.05% in a glycerin-in-castor oil 
emulsion (Table 1). More than 70% of the patients had 
symptoms of dry eye, 63% of the patients had a surgery 
history or other medical treatment, and 98% of the 
patients had an eye surgery history or other eye 
treatment (Table 2). 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Ingredients of each Staining Solution 
BSS 
Cyclosporine 
0.05% 
emulsion 
Lipid-based artificial 
tears containing omega-3 
Sodium chloride 
0.64% 
Cyclosporine 
0.05% 
Carboxymethylcellulose 
sodium 0.5% 
Potassium chloride 
0.075% 
Glycerin Glycerin 1% 
Calcium chloride 
dihydrate 0.048% 
Castor oil Polysorbate 80 0.5% 
Magnesium 
chloride 
hexahydrate 0.03% 
Polysorbate 
80 
Boric acid 
Sodium acetate 
trihydrate 0.39% 
Carbomer 
type A 
Butylated hydroxyl 
toluene 
Sodium citrate 
dihydrate 0.17% 
Purified 
water 
Castor oil 
Sodium hydroxide Sodium 
hydroxide 
Erythritol 
Hydrochloric acid  Flaxseed oil 
Water  Levocarnitine 
  Permulen TR-2 
  Polyoxyl 40 stearate 
  Purified water 
  Sodium hydroxide 
  Trehalose 
BSS: Balanced Salt Solution 
 
 
Table 2: Demographic and Clinical Information of the 173 
Patients 
Variable Values 
Age 68.36 ± 11.98 
Gender (% of women) 127 (73.41) 
Dry eye symptoms  
Yes 127 (73.41) 
No 46 (26.59) 
Surgery history or other 
medical treatment 
109 (63.01) 
Eye surgery history or other 
eye treatment 
170 (98.27) 
Data are presented as Mean ± SD or No. (%) 
 
Of the 173 eyes stained with sodium fluorescein in BSS, 
130 (75%) showed positive staining and 43 (25%) showed 
negative staining. Of the 43 eyes with negative staining, 
28 were stained with sodium fluorescein in BSS + 
cyclosporine 0.05% emulsion, and 15 were stained with 
sodium fluorescein in BSS + lipids containing omega-3. Of 
the 28 eyes stained with sodium fluorescein in BSS + 
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cyclosporine 0.05% emulsion, 25 (89%) showed positive 
staining. Of the 15 eyes stained with sodium fluorescein 
in BSS + lipids containing omega-3, 10 (67%) showed 
positive staining. Of the 5 eyes that showed negative 
staining with BSS + lipids containing omega-3, 4 (80%) 
showed positive staining with BSS + cyclosporine 0.05% 
emulsion (Table 3). 
 
Table 3: Staining Rate for each Condition 
Condition n Staining rate (95% 
CI) 
BSS only 173 0.75 (0.68–0.81) 
BSS + Cyclosporine 28 0.89 (0.73–0.96) 
BSS + Lipids containing omega-3 15 0.67 (0.42–0.85) 
BSS + Lipids containing omega-3 
+ Cyclosporine 
5 0.80 (0.38–0.99) 
CI: Confidence Interval 
 
DISCUSSION 
Our results showed that compared to BSS alone, artificial 
tears with cyclosporine 0.05% emulsion and lipids 
containing omega-3 remain in the cornea for longer 
periods. 
Due to the poor aqueous solubility of cyclosporine itself, 
cyclosporine 0.05% solution is formulated as a glycerin-
in-castor oil emulsion to allow easier administration of 
the drug to the eye [11]. The emulsion allows the lipids 
to remain in the cornea for longer times, thus allowing 
the clinician to detect small punctate corneal staining 
with sodium fluorescein. It also makes it more difficult to 
wash out the staining by the patient’s tears during 
examination under strong light. Commercially available 
Restasis® ; Allergan Inc, Irvine, CA comprises 0.05% 
cyclosporine in a homogenous emulsion of glycerin 
(2.2%), castor oil (1.25%), polysorbate 80 (1.00%), 
carbomer copolymer type A (0.05%), purified water (to 
100%), and sodium hydroxide for pH adjustment [12]. 
Although all other ingredients besides cyclosporine can 
be found in other artificial tear products, they do not 
exist in emulsion form. Artificial tears contain lipids such 
as omega-3, which also allow for better visualization of 
punctate lesions compared to BSS alone. However, in this 
study, BSS + cyclosporine 0.05% emulsion was able to 
identify punctate lesions that were undetectable using 
BSS + lipids containing omega-3. Since both cyclosporine 
0.05% emulsion and lipid-based artificial tears containing 
omega-3 contain water, just like BSS does, it would be 
expected that they would all allow sodium fluorescein 
staining of the cornea. Further comparative study in this 
regard is warranted to answer this question. There are 
many objective methods for DED diagnosis, namely the 
tear osmolarity test [13], tear matrix metalloproteinase 9 
level [14], meibography [15, 16], lipid layer thickness 
[17], TBUT [16], confocal microscopy, and severity of 
punctate staining. In this study, we subjectively 
evaluated the corneal punctate staining and TBUT first 
before proceeding with objective methods, since this is a 
simple, fast, and economic method. In this study, we also 
tested if the eye drop caused stinging sensation. 
However, none of the patients complained of stinging 
sensation, probably due to the minimum amount of 
Restasis® ; Allergan Inc, Irvine, CA applied to each sodium 
fluorescein strip. 
If excessive tear secretion occurs in a patient for various 
reasons, sodium fluorescein in BSS may be quickly 
washed out (wash-out effect) without sufficient staining 
for the examiner to visualize the punctuate lesions or 
determine the TBUT. The emulsion component of 
cyclosporine 0.05% solution remains longer in the 
cornea, thus providing more time for examination. 
However, in this study, sequential staining with different 
solutions may have contributed with the added effect of 
previous sodium fluorescein in the cornea. A future 
prospective controlled study to compare BSS with 
cyclosporine is warranted. In addition, it would be 
important to repeat this study in multiple centers, 
perhaps using additional artificial tear solutions. The 
results of this study can change the practice of initial 
diagnosis of DED before using expensive diagnostic 
equipment. It may also change the management 
associated with DED, such as in refractive surgery and 
glaucoma. In addition, lipid-containing emulsions should 
be investigated in “real-world” settings for diagnosing 
and treating DED as it may stabilize the tear film [18]. An 
efficient staining could assist in the differential diagnosis 
of non-DED ocular surface diseases such as anterior 
blepharitis, allergic conjunctivitis, corneal epithelial 
basement membrane dystrophy, contact lens 
intolerance, conjunctivochalasis, and keratoneuralgia 
[19]. The results of this study suggest that there are 25% 
of misdiagnosed DED cases by staining in BSS. Some DED 
cases may be diagnosed as neurotropic keratopathy 
while extensive diagnosis and treatment may be 
unnecessary [20]. As far as the authors know, numerous 
studies have described corneal staining with lissamine 
green, fluorescein, or rose Bengal dye, but none has 
discussed the best solution for efficient examination 
under slit lamp microscopy. We found that using lipid-
free solutions such as BSS or artificial tears may lead to 
misdiagnosis of cornea punctate lesions in 14–25% of 
cases. This study has one important limitation. We did 
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not diagnose the types of DED. However, it appeared 
that all patients had mixed DED (the most common type 
of DED). Differential diagnosis would require expensive 
testing and more time, and it was not pertinent to this 
study. In conclusion, if sodium fluorescein in BSS cannot 
confirm the punctate lesions in the cornea and 
determine TBUT, using cyclosporine 0.05% emulsion or 
lipid-based artificial tears could help retain sodium 
fluorescein for longer periods in the cornea, thus 
allowing the visualization of punctate lesions and 
evaluation of TBUT for DED diagnosis and follow-up. 
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